Trial · NCT06951503
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
NCT06951503, Phase 3, Recruiting, Akeso
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer. Trials, record NCT06951503. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06951503
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
- NCT number
- NCT06951503
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 560 participants, estimated
- Lead sponsor
- Akeso
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU, Bevacizumab
- First posted
- 2025-04-30
- Last updated
- 2026-03-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) assessed by blinded independent central review (BICR) | Up to approximately 3 years | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first (based on RECIST 1.1 criteria). |
| Secondary | Overall survival (OS) | Up to approximately 5 years | OS is defined as the time from randomization to death due to any cause. |
| Secondary | Progression-free survival (PFS) assessed by investigator | Up to approximately 3 years | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first (based on RECIST 1.1 criteria). |
| Secondary | Objective Response Rate (ORR) | Up to approximately 3 years | ORR is defined as proportion of subjects who have a complete or partial response relative to baseline according to RECIST 1.1 criteria. |
| Secondary | Duration of Response (DoR) | Up to approximately 3 years | DoR is defined as the duration from the first documentation of objective response to the first documented disease progression(based on RECIST v1.1 criteria) or death due to any cause, whichever occurs first. |
| Secondary | Disease control rate (DCR) | Up to approximately 3 years | DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST v1.1 criteria). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06951503
GET https://conductscience.org/api/trials/v1/NCT06951503/registered